Seeking Alpha

Bristol-Myers submits NDAs for Hep C drugs

  • Bristol-Myers Squibb (BMY +0.2%) submits new drug applications to the FDA for its NS5A replication complex inhibitor daclatasvir (DVC) and its NS3 protease inhibitor asunaprevir (ASV) for the treatment of Hepatitis C.
  • The regulatory agency recently designated the drugs Breakthrough Therapies.
  • The European Medicines Agency and Japan's Pharmaceutical and Medical Devices Agency are also reviewing the products under accelerated processes.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs